ES2527455T3 - Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes - Google Patents

Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes Download PDF

Info

Publication number
ES2527455T3
ES2527455T3 ES10725863.4T ES10725863T ES2527455T3 ES 2527455 T3 ES2527455 T3 ES 2527455T3 ES 10725863 T ES10725863 T ES 10725863T ES 2527455 T3 ES2527455 T3 ES 2527455T3
Authority
ES
Spain
Prior art keywords
cirrhosis
biomarkers
human plasma
clinical diagnosis
plasma proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10725863.4T
Other languages
English (en)
Inventor
Raymond A. Dwek
Bevin Gangadharan
Nicole Zitzmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
Original Assignee
University of Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Oxford filed Critical University of Oxford
Application granted granted Critical
Publication of ES2527455T3 publication Critical patent/ES2527455T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4728—Details alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7057—(Intracellular) signaling and trafficking pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Un procedimiento de detección y evaluación de la gravedad de la fibrosis o cirrosis hepática, que comprende: a) determinar el nivel de al menos un polipéptido asociado a HF en una muestra biológica obtenida de un paciente; y b) comparar dicho nivel de (a) con un nivel de control de dicho polipéptido asociado a HF para determinar un diagnóstico positivo o negativo de dicha fibrosis o cirrosis; en el que dicho al menos un polipéptido asociado a HF comprende proteína zeta/delta 14-3-3; y en el que la muestra biológica es suero o plasma.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
ES10725863.4T 2009-05-14 2010-05-13 Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes Active ES2527455T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17833409P 2009-05-14 2009-05-14
US178334P 2009-05-14
PCT/IB2010/001343 WO2010133967A1 (en) 2009-05-14 2010-05-13 Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers

Publications (1)

Publication Number Publication Date
ES2527455T3 true ES2527455T3 (es) 2015-01-23

Family

ID=42663624

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14175203T Active ES2897692T3 (es) 2009-05-14 2010-05-13 Diagnóstico clínico de la fibrosis hepática mediante un nuevo grupo de biomarcadores de proteínas plasmáticas humanas poco abundantes
ES10725863.4T Active ES2527455T3 (es) 2009-05-14 2010-05-13 Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14175203T Active ES2897692T3 (es) 2009-05-14 2010-05-13 Diagnóstico clínico de la fibrosis hepática mediante un nuevo grupo de biomarcadores de proteínas plasmáticas humanas poco abundantes

Country Status (8)

Country Link
US (3) US8889364B2 (es)
EP (2) EP2799876B1 (es)
JP (3) JP5813630B2 (es)
KR (1) KR20120041175A (es)
CN (2) CN105866423A (es)
CA (1) CA2761692A1 (es)
ES (2) ES2897692T3 (es)
WO (1) WO2010133967A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100706385B1 (ko) * 2005-09-16 2007-04-10 주식회사 팬택앤큐리텔 이동통신 시스템에서 바이러스치료기능을 갖는이동통신단말기
US8889364B2 (en) * 2009-05-14 2014-11-18 The Chancellor, Masters And Scholars Of The University Of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
US20130084276A1 (en) * 2010-01-26 2013-04-04 The Heartbeat Trust Limited Biomarkers of cardiovascular disease including lrg
CN102183661B (zh) * 2011-03-16 2014-05-28 天津宝瑞生物技术有限公司 蛋白质及蛋白质组在制备肝硬化诊断试剂中的应用
EP2836608A4 (en) * 2012-04-13 2016-02-24 Somalogic Inc TUBERCULOSIS BIOMARKERS AND USES THEREOF
WO2015014763A2 (en) * 2013-08-02 2015-02-05 Echosens Non-invasive system for calculating a human or animal, reliable, standardized and complete score
GB201315747D0 (en) * 2013-09-04 2013-10-16 Cambridge University Hospitals Nhs Foundation Trust Biomarkers associated with diabetes and firosis
CN104330570B (zh) * 2014-10-11 2016-03-16 中国科学院微生物研究所 人热休克蛋白gp96在制备筛查肝病的产品中的应用
CN105301259A (zh) * 2015-10-10 2016-02-03 广西医科大学 血清rbp4蛋白作为肝癌病人血清标志物及其应用
WO2017139455A1 (en) * 2016-02-10 2017-08-17 Wake Forest University Health Sciences Model system of liver fibrosis and method of making and using the same
GB201614455D0 (en) 2016-08-24 2016-10-05 Univ Oxford Innovation Ltd Biomarkers
CN106198985B (zh) * 2016-08-31 2018-03-27 天津市泌尿外科研究所 用于检测去势抵抗性前列腺癌的elisa试剂盒及使用方法
EP3470843A1 (en) * 2017-10-16 2019-04-17 Biopredictive Method of prognosis of primary liver cancer
CN111279195B (zh) * 2017-10-16 2024-01-23 生物预测公司 原发性肝癌的预后和随访方法
EP3511716A1 (en) * 2018-01-16 2019-07-17 Koninklijke Philips N.V. Periodontitis diagnostic methods, uses and kits
EP3553520A1 (en) * 2018-04-12 2019-10-16 Koninklijke Philips N.V. Methods, uses and kits for monitoring or predicting response to periodontal disease treatment
CN110221337B (zh) * 2019-06-28 2022-07-01 南华大学 一种利用α-1抗蛋白酶评价铀矿粉尘内照射生物损伤的方法
WO2021107105A1 (ja) * 2019-11-29 2021-06-03 積水メディカル株式会社 免疫反応を利用したアナライトの測定方法及び測定試薬
CN111239408B (zh) * 2020-01-19 2023-02-10 深圳格道糖生物技术有限公司 特定凝集素组合在构建基于唾液糖蛋白糖链鉴别肝纤维化的测试工具方面的应用
CN111751551B (zh) * 2020-06-08 2023-03-17 郑州大学第一附属医院 蛋白分子作为诊断肝硬化的生物标志物及其预后方法
CN114113624B (zh) * 2020-08-28 2024-08-16 香港城市大学深圳研究院 利用免疫球蛋白关联蛋白质组开发疾病标志物的方法及装置
CN114527275A (zh) * 2022-02-22 2022-05-24 深圳市亚辉龙生物科技股份有限公司 肝纤维化的诊断试剂盒
CN115436622B (zh) * 2022-09-26 2024-03-08 重庆医科大学国际体外诊断研究院 一种单分子蛋白的检测方法及其试剂盒和应用
CN115651065A (zh) * 2022-12-09 2023-01-31 杭州普望生物技术有限公司 一种用于肝纤维化和肝硬化检测的试剂盒

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) * 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US6897287B1 (en) * 1990-01-31 2005-05-24 Oklahoma Medical Research Foundation Ro/SSA peptide reagents for diagnosis of autoantibodies
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US5371021A (en) * 1992-07-17 1994-12-06 Beckman Instruments, Inc. Initial rate photometric method for immunoassay
US6631330B1 (en) * 2000-08-21 2003-10-07 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of inflammatory, fibrotic or cancerous disease using biochemical markers
JP2004507740A (ja) 2000-08-21 2004-03-11 アシスタンス　ピュブリック−オピト　ド　パリ 生化学マーカーを用いる繊維性疾患の診断方法
DE10115083A1 (de) * 2001-03-27 2002-10-10 Schebo Biotech Ag Nachweis von Milchdrüsenentzündungen
US20030199000A1 (en) * 2001-08-20 2003-10-23 Valkirs Gunars E. Diagnostic markers of stroke and cerebral injury and methods of use thereof
CN100415899C (zh) * 2001-09-05 2008-09-03 普赖德普罗特奥米克斯公司 Ii型糖尿病蛋白质
CA2473781A1 (en) * 2002-01-18 2003-07-31 Protemix Corporation Limited Glycoisoforms of adiponectin and uses thereof
US6986995B2 (en) 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
JP2005522677A (ja) * 2002-04-08 2005-07-28 シファーゲン バイオシステムズ， インコーポレイテッド 肝細胞癌の血清バイオマーカー
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
US20050112706A1 (en) * 2002-11-07 2005-05-26 Susan Kasper Diagnostic and prognostic methods for prostate cancers
ES2543160T3 (es) 2003-01-14 2015-08-17 Vib Vzw Un marcador de suero para medir fibrosis hepática
WO2004081029A2 (en) * 2003-03-13 2004-09-23 Ramot At Tel Aviv University Ltd. Novel non-invasive marker for liver disease
AU2003901239A0 (en) * 2003-03-18 2003-04-03 Children's Cancer Institute Australia for Medical Research Determining drug resistance
WO2005055925A2 (en) 2003-09-10 2005-06-23 Board Of Regents, The University Of Texas System 14-3-3 zeta over-expression as a poor prognosis factor, and a therapeutic target in multiple cancer types
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
TWI281473B (en) 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
FR2870348B1 (fr) 2004-05-14 2010-08-27 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet
EP1626279B1 (en) * 2004-08-12 2008-04-16 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
EP1626280B1 (en) * 2004-08-12 2007-02-14 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
WO2006071469A2 (en) 2004-12-02 2006-07-06 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Modulation of the neuroendocrine system as a therapy for amyotrophic lateral sclerosis
US7860656B2 (en) * 2005-02-03 2010-12-28 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of hepatic steatosis using biochemical markers
WO2006089586A1 (en) 2005-02-23 2006-08-31 Medizinische Universität Graz Use of a compound with clusterin activity for the treatment of diseases associated with the deposition of abnormal proteins
JP2006300689A (ja) * 2005-04-20 2006-11-02 Mcbi:Kk 肝疾患病態判定用マーカー及び該マーカーを用いる肝疾患病態判定方法
ES2743543T3 (es) 2005-05-05 2020-02-19 Univ Drexel Diagnóstico de patología hepática a través de la evaluación del quininógeno fucosilado
JP2007024631A (ja) * 2005-07-14 2007-02-01 Human Science Shinko Zaidan 同位体標識法
EP1949105A4 (en) 2005-10-11 2009-06-17 Tethys Bioscience Inc DIABETES ASSOCIATED MARKERS AND METHOD FOR USE THEREOF
US7972802B2 (en) * 2005-10-31 2011-07-05 University Of Washington Lipoprotein-associated markers for cardiovascular disease
US20070117100A1 (en) * 2005-11-18 2007-05-24 Sun-Lung Tsai Biomarker for determining predisposition and/or prognosis of hepatocellular carcinoma
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
US20090035801A1 (en) * 2005-12-27 2009-02-05 Power3 Medical Products, Inc. Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer
CN101074958A (zh) * 2006-05-17 2007-11-21 上海森雄科技实业有限公司 一种层粘连蛋白诊断试剂盒
ATE483742T1 (de) * 2006-05-18 2010-10-15 Dow Global Technologies Inc Polyurethan-elastomer mit erhöhter hydrolyse- resistenz
WO2008031051A2 (en) * 2006-09-08 2008-03-13 United Therapeutics Corporation Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
US20080161203A1 (en) * 2006-12-27 2008-07-03 Su Chun-Lin Markers identified for liver fibrosis and cirrhosis and the microarray panel thereof
CN101003831A (zh) * 2007-01-17 2007-07-25 王贤理 肝胆系统疾病诊断试剂盒
US9000134B2 (en) * 2007-05-11 2015-04-07 Wallace B. Haigh Reagent and kit for early diagnosis of kidney disease
CN101353696A (zh) * 2007-07-24 2009-01-28 财团法人工业技术研究院 包括肝纤维化和/或肝硬化的肝纤维损伤的生物标志及其检测方法
CN101275951A (zh) * 2007-08-17 2008-10-01 赛亚基因科技股份有限公司 鉴定肝纤维化及肝硬化的分子标记及其微阵列系统板
KR100970652B1 (ko) * 2007-10-24 2010-07-15 남명진 폐암 진단용 키트
CN101368969A (zh) * 2008-03-14 2009-02-18 北京科美东雅生物技术有限公司 Ⅳ型胶原蛋白化学发光免疫分析定量测定试剂盒及其制备方法
WO2010005387A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab New method and biomarkers for the diagnosis of multiple sclerosis
WO2010079253A2 (es) * 2009-01-09 2010-07-15 Proyecto De Biomedicina Cima, S.L. Biomarcadores para el diagnóstico de fibrosis
EP2211182A1 (en) * 2009-01-16 2010-07-28 Roche Diagnostics GmbH Method for the assessment of severity of liver cirrhosis
US8889364B2 (en) * 2009-05-14 2014-11-18 The Chancellor, Masters And Scholars Of The University Of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers

Also Published As

Publication number Publication date
CN102460174A (zh) 2012-05-16
JP2016138891A (ja) 2016-08-04
CA2761692A1 (en) 2010-11-25
JP5813630B2 (ja) 2015-11-17
US20150105293A1 (en) 2015-04-16
KR20120041175A (ko) 2012-04-30
ES2897692T3 (es) 2022-03-02
JP5897638B2 (ja) 2016-03-30
US8889364B2 (en) 2014-11-18
HK1166368A1 (zh) 2012-10-26
JP2012526980A (ja) 2012-11-01
EP2799876A3 (en) 2015-07-29
US20160202274A1 (en) 2016-07-14
CN105866423A (zh) 2016-08-17
EP2430451A1 (en) 2012-03-21
CN102460174B (zh) 2016-03-16
EP2430451B1 (en) 2014-08-13
WO2010133967A1 (en) 2010-11-25
JP2014197006A (ja) 2014-10-16
US20100291602A1 (en) 2010-11-18
EP2799876B1 (en) 2021-11-03
EP2799876A2 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
ES2527455T3 (es) Diagnóstico clínico de fibrosis/cirrosis hepática usando biomarcadores de proteínas plasmáticas humanas poco abundantes
Fan et al. Diagnosing sepsis–The role of laboratory medicine
Cabiati et al. Osteopontin in hepatocellular carcinoma: A possible biomarker for diagnosis and follow-up
ES2524723T3 (es) Fructosil peptidil oxidasa y un sensor para analizar una proteína glucosilada
Hoffmann et al. Human papillomavirus infection in head and neck cancer: the role of the secretory leukocyte protease inhibitor
WO2008041953A3 (en) Dengue diagnosis and treatment
RU2015136673A (ru) Биомаркеры сахарного диабета 2 типа и их применение
IL257330A (en) Compositions, methods and kits for diagnosis of lung cancer
JP2016538545A5 (es)
Khattab et al. Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4
PE20200479A1 (es) Ensayos de diagnostico para detectar, cuantificar y/o rastrear microbios y otros analitos
ES2530979T3 (es) Detección de ácidos nucleicos y proteínas
Chen et al. Proteomic analysis identifies prolonged disturbances in pathways related to cholesterol metabolism and myocardium function in the COVID-19 recovery stage
BR112012017014A8 (pt) métodos para detecção de anticorpos de vírus jc
BR112014011563A2 (pt) métodos para detectar o papiloma-vírus humano e fornecer o prognóstico para carci-noma de células escamosas de cabeça e pescoço
ATE390633T1 (de) Reagens zum nachweis eines morbus-alzheimer- risikofaktors, nachweiskit dafür und verfahren zum nachweis eines morbus-alzheimer-risikofaktors unter verwendung davon
ES2601028T3 (es) Método de medición inmunológica para el precursor del péptido liberador de gastrina
Yue et al. Probing the spatiotemporal patterns of HBV multiplication reveals novel features of its subcellular processes
Ayorinde et al. Clinical and biomarker assessment of frailty in liver transplantation
ATE475884T1 (de) Detektion von zirkulierenden endothelzellen
JP2008538812A5 (es)
Isac et al. Dynamics of serum α-fetoprotein in viral hepatitis C without hepatocellular carcinoma
ES2564186T3 (es) Uso para fines de cribado de activos anti-envejecimiento de formas solubles de la proteína del tipo desmogleína I
Sabry et al. Effect of vitamin D therapy on interleukin-6, visfatin, and hyaluronic acid levels in chronic hepatitis C Egyptian patients
ES2418459B1 (es) Relacionando agregación proteica con supervivencia de levadura